

Table 21.16

## Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,756	91.6%	20,308	92.2%	2,063	87.5%	2,109	91.1%	118	86.1%	3,178	87.5%
Epidermoid carcinoma <sup>d</sup> (8051-8131)	172	0.6%	130	0.6%	17	0.7%	25	1.1%	-	-	32	0.9%
Adenocarcinoma <sup>e</sup>	22,797	84.3%	18,817	85.4%	1,793	76.1%	1,937	83.7%	109	79.6%	2,881	79.3%
Adenocarcinoma, NOS (8140)	2,891	10.7%	2,353	10.7%	350	14.8%	159	6.9%	-	-	353	9.7%
Papillary adenocarcinoma, NOS (8050,8260)	266	1.0%	215	1.0%	28	1.2%	17	0.7%	-	-	33	0.9%
Clear cell adenocarcinoma (8310,9110)	1,478	5.5%	1,108	5.0%	76	3.2%	275	11.9%	-	-	166	4.6%
Endometrioid carcinoma (8380-8383,8570)	2,668	9.9%	2,169	9.8%	145	6.2%	324	14.0%	-	-	415	11.4%
Cystadenocarcinoma, NOS (8440,8450)	61	0.2%	48	0.2%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	7,751	28.7%	6,517	29.6%	596	25.3%	550	23.8%	41	29.9%	858	23.6%
Papillary serous cystadenocarcinoma (8460-8462)	4,807	17.8%	4,068	18.5%	391	16.6%	302	13.0%	21	15.3%	612	16.9%
Mucinous cystadenocarcinoma (8470-8473)	328	1.2%	257	1.2%	21	0.9%	46	2.0%	-	-	45	1.2%
Mucinous adenocarcinoma (8480,8482)	1,082	4.0%	861	3.9%	88	3.7%	118	5.1%	-	-	161	4.4%
Mucin-producing adenocarcinoma(8481)	26	0.1%	19	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma <sup>f</sup>	1,439	5.3%	1,202	5.5%	87	3.7%	138	6.0%	-	-	224	6.2%
Other specific carcinomas <sup>g</sup>	670	2.5%	464	2.1%	143	6.1%	50	2.2%	-	-	111	3.1%
Stromal cell tumor (8620-8631,8650)	487	1.8%	324	1.5%	119	5.0%	33	1.4%	-	-	83	2.3%
Other <sup>h</sup>	183	0.7%	140	0.6%	24	1.0%	17	0.7%	-	-	28	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,117	4.1%	897	4.1%	110	4.7%	97	4.2%	-	-	154	4.2%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).  
Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

<sup>f</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

<sup>g</sup> Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

<sup>h</sup> Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

<sup>i</sup> Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

## Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	84	0.3%	60	0.3%	16	0.7%	-	-	-	-	21	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,890	7.0%	1,439	6.5%	231	9.8%	172	7.4%	-	-	392	10.8%
Mullerian mixed tumor (8950-8951,8980)	892	3.3%	739	3.4%	85	3.6%	53	2.3%	-	-	109	3.0%
Teratoma, malignant (9080-9085,9102)	404	1.5%	264	1.2%	67	2.8%	54	2.3%	-	-	145	4.0%
Other	594	2.2%	436	2.0%	79	3.4%	65	2.8%	-	-	138	3.8%
Unspecified (8000-8005)	301	1.1%	218	1.0%	47	2.0%	28	1.2%	-	-	40	1.1%
Total <sup>d</sup>	27,031	100.0%	22,025	100.0%	2,357	100.0%	2,315	100.0%	137	100.0%	3,631	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>d</sup> Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.